17.33
Schlusskurs vom Vortag:
$17.81
Offen:
$17.81
24-Stunden-Volumen:
3.36M
Relative Volume:
0.54
Marktkapitalisierung:
$5.37B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-124.55M
KGV:
-39.45
EPS:
-0.4393
Netto-Cashflow:
$-95.58M
1W Leistung:
+16.37%
1M Leistung:
+12.38%
6M Leistung:
+646.14%
1J Leistung:
+1,399%
Erasca Inc Stock (ERAS) Company Profile
Firmenname
Erasca Inc
Sektor
Branche
Telefon
(858) 465-6511
Adresse
3115 MERRYFIELD ROW, SAN DIEGO
Compare ERAS vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
|
ERAS
Erasca Inc
|
17.29 | 5.54B | 0 | -124.55M | -95.58M | -0.4393 |
|
VRTX
Vertex Pharmaceuticals Inc
|
433.53 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
761.09 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
747.05 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
330.56 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
INSM
Insmed Inc
|
163.57 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Erasca Inc Stock (ERAS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-27 | Fortgesetzt | Mizuho | Outperform |
| 2026-01-07 | Eingeleitet | Piper Sandler | Overweight |
| 2025-10-16 | Eingeleitet | Stifel | Buy |
| 2025-09-03 | Herabstufung | BofA Securities | Buy → Underperform |
| 2025-08-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-03-26 | Eingeleitet | Raymond James | Outperform |
| 2024-11-18 | Eingeleitet | Jefferies | Buy |
| 2024-03-11 | Eingeleitet | CapitalOne | Overweight |
| 2024-01-05 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-10-11 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-03-30 | Eingeleitet | Mizuho | Buy |
| 2023-02-24 | Eingeleitet | Goldman | Buy |
| 2023-02-03 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
Alle ansehen
Erasca Inc Aktie (ERAS) Neueste Nachrichten
JPMorgan Chase & Co. Has $2.77 Million Stock Holdings in Erasca, Inc. $ERAS - MarketBeat
5 Best Performing Stocks of Q1 2026 to Watch for Q2 - Insider Monkey
JPMorgan and Stifel Enhance Erasca’s Market Prospects with High Price Targets - timothysykes.com
Erasca CLO Ebun Garner sells $1.3m in ERAS stock By Investing.com - au.investing.com
Insider Selling: Erasca (NASDAQ:ERAS) Insider Sells 80,000 Shares of Stock - MarketBeat
Erasca CLO Ebun Garner sells $1.3m in ERAS stock - Investing.com
Erasca (ERAS) Chief Legal Officer exercises options, sells 80K shares under 10b5-1 plan - Stock Titan
Erasca (NASDAQ:ERAS) Trading 8.2% HigherHere's What Happened - MarketBeat
Erasca Inc stock hits 52-week high at $14.63 - investing.com
Erasca Inc stock hits 52-week high at 16.41 USD By Investing.com - Investing.com South Africa
Erasca reports proposed 80,000-share sale (NASDAQ: ERAS) - Stock Titan
Erasca (NASDAQ:ERAS) Hits New 1-Year HighShould You Buy? - MarketBeat
Erasca Inc stock hits 52-week high at 16.41 USD - investing.com
IBRX stock notches strongest quarter ever — but these 2 smaller biotech plays ran even hotter - MSN
ERAS Technical Analysis & Stock Price Forecast - Intellectia AI
Revenue Check: How does Erasca Inc perform in inflationary periods2026 Institutional & Daily Risk Controlled Trade Plans - baoquankhu1.vn
Erasca (ERAS) price target increased by 42.72% to 14.99 - msn.com
Erasca CMO's Direct Stake Hit Zero. Her Options Position Didn't - Yahoo Finance
Erasca (NASDAQ:ERAS) Shares Up 8.8%Should You Buy? - MarketBeat
Erasca’s Stock Surges Higher Amid Pipeline Optimism - StocksToTrade
Erasca’s HERKULES-3 Trial Reaches Completion: What Investors Should Watch in ERAS-007 - TipRanks
TNGX stock hits record high on inking collaboration deal with ERAS - MSN
Erasca (ERAS) adds 13%; soars 310% YTD - MSN
Mizuho initiates Erasca (ERAS) with 'outperform' rating and $16 PT - msn.com
Assessing Erasca (ERAS) Valuation After ERAS-0015 Licensing Win And Data Anticipation - Yahoo Finance
Certain Stock Options of Erasca, Inc. are subject to a Lock-Up Agreement Ending on 23-MAR-2026. - MarketScreener
A Look At Erasca (ERAS) Valuation After Its Strong Recent Share Price Rally - simplywall.st
How Erasca’s Expanded ERAS-0015 License and Narrower 2025 Loss Will Impact Erasca (ERAS) Investors - simplywall.st
Erasca (ERAS) Adds 13%; Soars 310% YTD - Insider Monkey
5 Stocks Dominating Today’s Market Action - Insider Monkey
Erasca (NASDAQ:ERAS) Shares Up 10.3% on Better-Than-Expected Earnings - MarketBeat
Guggenheim more than doubles Erasca (ERAS) PT following clinical progress and updated pipeline models - MSN
ERAS Surges as JP Morgan Raises Price Target | ERAS Stock News - GuruFocus
JPMorgan Chase & Co. Increases Erasca (NASDAQ:ERAS) Price Target to $25.00 - MarketBeat
Analysts Offer Insights on Healthcare Companies: BeOne Medicines (ONC), Argenx Se (ARGX) and Erasca (ERAS) - The Globe and Mail
Erasca, Inc. (NASDAQ:ERAS) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Chipmakers Recap: Should I invest in Erasca Inc before earnings2026 Valuation Update & Weekly Sector Rotation Insights - baoquankhu1.vn
Erasca Form 144: Foundation Lists Proposed Common Sales | ERAS SEC FilingForm 144 - Stock Titan
Erasca (NASDAQ:ERAS) Stock Price Expected to Rise, Guggenheim Analyst Says - MarketBeat
Erasca’s Stock Faces Pressure as CMO Offloads Shares - StocksToTrade
uniQure, Syndax and Erasca Are Drawing Analyst Interest Ahead of Key Drug Catalysts - AOL.com
Erasca’s CMO Stock Sale Raises Eyebrows Amid Market Uncertainty - timothysykes.com
Finanzdaten der Erasca Inc-Aktie (ERAS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Erasca Inc-Aktie (ERAS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Garner Ebun | Chief Legal Officer |
Apr 01 '26 |
Sale |
16.40 |
80,000 |
1,312,000 |
25,076 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):